...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Free
Message: Clinical trials site
Reply New Message
Prev Message Back To Forum Threaded View Next Message
ClinicalTrials.gov Identifier: NCT05111561
Recruitment Status  : Recruiting
First Posted  : November 8, 2021
Last Update Posted  : August 19, 2022
Sponsor:
National Cancer Institute (NCI) 
Information provided by (Responsible Party):
National Cancer Institute (NCI)

 

Study Description
 
Go to 
Brief Summary:
This phase I trial tests the safety, side effects, and best dose of ZEN003694 in combination with Binimetinib in treating patients with solid tumors that carry RAS alterations and that have spread to other places in the body 
5 Recommendations
Reply New Message
Prev Message Back To Forum Threaded View Next Message
Share
Share
New Message
Please login to post a reply